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ABSTRACT
Introduction Compared with many other countries 
Russia has a high prevalence of diabetes in men and 
women. However, contrary to what is found in most other 
populations, the risk is greater among women than men. 
The reasons for this are unclear.
Research design and methods Prevalence and risk 
factors for diabetes at ages 40–69 years were compared 
in two population- based studies: Know Your Heart (KYH) 
(Russia, 2015–2018, n=4121) and the seventh wave of the 
Tromsø Study (Tromsø 7) (Norway, 2015–2016, n=17 649). 
Diabetes was defined by the level of glycated hemoglobin 
and/or self- reported diabetes and/or diabetes medication 
use. Marginal structural models were used to estimate the 
role of key risk factors for diabetes in differences between 
the studies.
Results Age- standardized prevalence of diabetes was 
higher in KYH compared with Tromsø 7 in men (11.6% 
vs 6.2%) and in women (13.2% vs 4.3%). Age- adjusted 
ORs for diabetes in KYH compared with Tromsø 7 were 
2.01 (95% CI 1.68 to 2.40) for men and 3.66 (95% CI 
3.13 to 4.26) for women. Adiposity (body mass index 
and waist circumference) explained none of this effect 
for men but explained 46.0% (39.6, 53.8) for women. 
Addition of smoking and C reactive protein, as further 
mediators, slightly increased the percentage explained of 
the difference between studies to 55.5% (46.5, 66.0) for 
women but only to 9.9% (−0.6, 20.8) for men.
Conclusions Adiposity is a key modifiable risk factor 
that appears to explain half of the almost threefold higher 
female prevalence of diabetes in Russia compared with 
Norway, but none of the twofold male difference.
INTRODUCTION
Diabetes has an independent effect on the 
risk of cardiovascular events1 and causes 
long- term microvascular complications.2 3 
The disease is heterogeneous in nature and 
progression and is broadly classified into 
type 1 diabetes and type 2 diabetes.4 Type 2 
diabetes is strongly associated with obesity 
and related lifestyle factors and is the most 
common type in adults.4
Population aging and the worldwide rise in 
obesity have contributed to the marked rise in 
type 2 diabetes prevalence in many countries, 
although there remains substantial inter-
national variation.5 Data on type 2 diabetes 
prevalence in Russia have been reported in a 
few population- based studies based either on 
glycated hemoglobin6–8 or fasting glucose.9–11 
These studies report relatively high preva-
lence of type 2 diabetes in Russia ranging from 
7% to 16%, with the highest burden being in 
women compared with men at older ages. 
Significance of this study
What is already known about this subject?
 ► Russia has strikingly higher diabetes rates com-
pared with Western countries occurring within the 
context of a very high mortality from cardiovascular 
disease and low life expectancy at birth.
 ► Unlike many other countries diabetes is more com-
mon among women than men at older ages.
What are the new findings?
 ► Obesity and measures of adiposity contribute sub-
stantially to the higher prevalence of diabetes 
among women in Russia compared with women in 
Norway; however, obesity did not explain differences 
in diabetes prevalence among men between the two 
countries.
 ► Even after accounting for obesity and other risk fac-
tors, diabetes prevalence remained a lot higher in 
the Russian study than in Norway for both sexes.
 ► The proportion of undiagnosed diabetes in Russia is 
much higher than in Norway.
How might these results change the focus of 
research or clinical practice?
 ► Strategies to reduce levels of adiposity in the 
Russian population are important, with a need to 
focus on reducing levels in women.
 ► The proportion of undiagnosed diabetes in Russia 
should be reduced by targeted screening efforts.
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The notably higher prevalence in women compared with 
men is atypical compared with many other countries.4 5 
The high prevalence of diabetes in Russia compared with 
the neighboring countries in Western Europe is of partic-
ular interest because this may contribute to the very 
high levels of cardiovascular disease (CVD) in Russia.12 
However, no systematic attempt has been made previ-
ously to investigate which risk factors may explain the 
relatively high prevalence of diabetes in Russia compared 
with elsewhere.
At early stages symptoms of type 2 diabetes are absent or 
remain unnoticed; therefore a substantial proportion of 
type 2 diabetes remain undiagnosed and not managed.13 
Previous studies in Russia reported a very high propor-
tion of undiagnosed diabetes (up to 54%).8 This can lead 
to delay in management of the condition and health-
care interventions directed to reduce cardiometabolic 
risk factors such as hypercholesterolemia, hypertension, 
hypoglycemia, and obesity.
In this study we aim to investigate whether high diabetes 
prevalence in Russia compared with Norway is explained 
by known risk factors of diabetes. We used data collected 
in two recent cross- sectional, population- based studies 
conducted in Russia and Norway that defined diabetes 
in a comparable manner. These countries share a border 
and have similar population age structure.
METHODS
Study populations
We used data on men and women aged 40–69 years who 
took part in two population- based studies. The Know Your 
Heart (KYH) study14 is a cross- sectional study conducted 
in Russia in 2015–2017. The seventh wave of Tromsø 
Study (Tromsø 7)15 was conducted among the residents 
of the municipality of Tromsø (Norway) in 2015–2016.
Know Your Heart (Russia)
A random population- based sample of participants 
aged 35–69 years old (n=5071) stratified by age, sex and 
district were recruited in Arkhangelsk and Novosibirsk 
cities (Russia). Trained interviewers visited the sampled 
addresses and recorded information about residents’ 
health, sociodemographic characteristics and lifestyle 
(51% of approached agreed to participate). Partici-
pants were then invited to take part in a health check 
that usually occurred 1–2 weeks later in a research clinic 
and 4512 (35–69 years old) agreed (89%). Our analysis is 
based on 4121 participants aged 40–69 years who attended 
the health check (online supplemental figure 1). The 
health check included a medical examination, ques-
tionnaire and biological sample collection. The medical 
examination included blood pressure measurements 
and recording of weight and height. The questionnaire 
collected data on health problems, lifestyle, and medica-
tion use. The blood samples were non- fasting, but partic-
ipants were asked not to eat and drink for 4 hours before 
the health check. Within 2 hours after venipuncture, 
blood samples were centrifuged, and serum was frozen 
at −80°C. Frozen samples were shipped to a laboratory in 
Moscow and analyzed in a single batch at the end of the 
fieldwork. Further details of the study design have been 
published elsewhere.14
Tromsø 7 (Norway)
All inhabitants of the municipality of Tromsø aged 40 
years and above were invited to take part in Tromsø 7 and 
21 083 participated (65%), of whom 17 649 aged 40–69 
years were included in our analysis (online supplemental 
figure 2). All participants completed the questionnaires 
and examinations including biological sampling. The 
questionnaire included a broad set of questions on life-
style, medication use, and disease. Blood samples (non- 
fasting) were processed immediately after collection and 
the laboratory assays of the biomarkers were done on the 
same day at the Department of Laboratory Medicine, 
University Hospital of Northern Norway (International 
Organization for Standardization (ISO) certification 
NS- EN ISO 15189:2012). Further details of the design of 
the Tromsø Study have been published elsewhere.15
Outcomes
The outcome of the study is the prevalence of diabetes 
mellitus, defined as glycated hemoglobin (HbA1c) >6.5% 
(48 mmol/mol)16 and/or self- reported diabetes and/
or use of medication for diabetes (online supplemental 
table 1). Use of medication for diabetes was collected 
based on answers to the question about diabetes medi-
cation use and/or drugs taken during the last 4 weeks 
coded with A10 (antidiabetics) of the Anatomical Ther-
apeutic Chemical classification.17 In KYH, diabetes self- 
report was determined from the question ‘Have you ever 
been told by a doctor or nurse that you have diabetes 
mellitus?’ In Tromsø 7, participants who answered that 
they currently have diabetes on the question ‘Have you 
or have you ever had diabetes?’ were recorded as having 
diabetes. A person with HbA1c ≥6.5% (48 mmol/mol) 
was considered undiagnosed if they did not report having 
diabetes or taking diabetes medications. Pre- diabetes was 
defined as HbA1c ≥5.7% (39 mmol/mol) and <6.5% 
(48 mmol/mol) among those who did not report that 
they have diabetes or take diabetes medications.16
HbA1c was measured in whole blood by immunotur-
bidimetric test on AU680 Chemistry System (Beckman 
Coulter) in KYH and by capillary electrophoresis on 
Capillarys 3 Tera with the MCA Laboratory HbA1c cali-
brator traceable to the International Federation of 
Clinical Chemistry reference measurement in Tromsø 
7. A calibration study between the two laboratories was 
conducted and HbA1c levels were adjusted appropriately 
to make them directly comparable.18
We were not able to distinguish between type 1 and 
type 2 diabetes in this study as consistent and comparable 
data on age at onset and other distinctive characteristics 
of these two conditions were not available.
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Exposure variables
Adiposity was assessed using body mass index (BMI) 
and waist circumference (WC). WC was measured at the 
narrowest part of the trunk (KYH) or at the umbilical 
level (Tromsø 7). To ensure comparability, WC in Tromsø 
7 was converted to the narrowest waist using a conver-
sion equation.19 Mean systolic and diastolic blood pres-
sure were calculated as the mean of the second and third 
measurements. Smoking was categorized as ex- smokers, 
never- smokers and current smokers (1–10 cigarettes per 
day, 11–20 cigarettes per day, >20 cigarettes per day). 
Total cholesterol, low- density lipoprotein (LDL) choles-
terol, high- density lipoprotein cholesterol, triglycerides, 
and high sensitivity C- reactive protein (hsCRP) were 
measured.14 18 A calibration study of the laboratory 
biomarkers was conducted to harmonize measurements 
between studies.18
All participants gave signed consent.
Statistical analysis
Sex- specific prevalence of diabetes, pre- diabetes, and 
undiagnosed diabetes in the two studies were compared 
after age standardization to the Standard European 
Population 2013.
To examine if the differences in prevalence of diabetes 
between studies may be explained by different levels 
of diabetes risk factors, we conducted mediation anal-
ysis using marginal structural models,20 which allow 
the decomposition of total effect of exposure into that 
mediated by specific factors (indirect effect) and the 
remaining (direct) effect. In our analysis, the study (KYH 
vs Tromsø 7) was considered the exposure, while diabetes 
risk factors were considered possible mediators. BMI and 
WC were added together at the first step of the mediation 
analysis to provide an estimate of the role of adiposity, 
and the independent effects were not examined.21 Both 
BMI and WC were modeled as quintiles to account for 
non- linearity of the association by diabetes (online 
supplemental figures 3 and 4); quintiles were defined 
based on the total study population of men and women 
from both studies. A further model introduced smoking 
and hsCRP as additional mediators, the latter as it reflects 
proinflammatory status.21 22 Mediation analysis was done 
stratified by sex, and age was treated as a confounder.
Statistical analysis was performed using R V.3.6.0 
(package medflex 0.66) and SAS V.9.4.
Sensitivity analysis
Self- report of diabetes diagnosis may not be fully reliable. 
We therefore conducted a sensitivity analysis for media-
tion analyses and comparison of CVD risk factor profile 
where defined diabetes was based on HbA1c values alone.
RESULTS
Age- standardized prevalence of diabetes, pre- diabetes 
and undiagnosed diabetes was higher in KYH compared 
with Tromsø 7 among men and women (table 1 and 
Table 1 Number of people and age- standardized prevalence* of diabetes, undiagnosed diabetes, and pre- diabetes in Know 
Your Heart and Tromsø 7, by sex
Know your Heart % (95% CI)† Tromsø 7 % (95% CI)†
Men (n) 1732 8349
  Diabetes cases (n)‡ 219 514
  Number of undiagnosed diabetes cases (n)§ 76 94
  Number of pre- diabetes cases (n)¶ 612 1875
  Diabetes mellitus prevalence‡ 11.6 (10.3 to 12.8) 6.2 (5.6 to 6.7)
  Undiagnosed diabetes§ 4.04 (3.4 to 4.7) 1.15 (0.9 to 1.4)
  Prevalence of pre- diabetes¶** 35.3 (33.2 to 37.4) 22.7 (21.8 to 23.6)
Women (n) 2389 9300
  Diabetes cases (n)‡ 361 395
  Number of undiagnosed diabetes cases (n)§ 91 48
  Number of pre- diabetes cases (n)¶ 824 2055
  Diabetes mellitus prevalence‡ 13.3 (12.3 to 14.2) 4.3 (3.8 to 4.8)
  Undiagnosed diabetes§ 3.5 (3.1 to 3.9) 0.5 (0.3 to 0.8)
  Prevalence of pre- diabetes¶** 35.1 (33.4 to 36.9) 22.6 (21.7 to 23.4)
*Age- standardized to the Standard European Population 2013; p<0.001 for all comparisons.
†All percentages are based on the total number of participants in Know Your Heart and Tromsø 7.
‡Diabetes defined as HbA1c ≥6.5% (48 mmol/mol) and/or self- reported diabetes and/or use of medication with ATC code A10 (antidiabetics) 
according to the Anatomical Therapeutic Chemical (ATC) classification.
§Undiagnosed diabetes defined as HbA1c ≥6.5% (48 mmol/mol), no self- reported diabetes and no diabetes medication use.
¶Pre- diabetes defined as HbA1c ≥5.7% (39 mmol/mol) and <6.5% (48 mmol/mol), no self- reported diabetes and no diabetes medication use.
**Missing data: Know Your Heart: HbA1c 124, diabetes medication 423; Tromsø 7: self- report of diabetes 413; HbA1c 212.
HbA1c, glycated hemoglobin.
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online supplemental table 1). The proportion of those 
with diabetes who were undiagnosed was higher in KYH 
than in Tromsø 7 both in younger and older age groups 
(table 2).
Next we compared cardiometabolic risk factor profiles 
among participants with diabetes and without diabetes in 
both studies (table 3). In both studies men and women 
with diabetes had higher BMI and WC, higher systolic 
and diastolic blood pressure, and higher hsCRP levels 
than those who do not have diabetes. In KYH levels of 
total and LDL- cholesterol were similar in participants 
with and without diabetes; however, in Tromsø 7 total and 
LDL- cholesterol were lower in participants with diabetes. 
Smoking prevalence was similar in participants with and 
without diabetes in both studies. Use of lipid- lowering 
drugs was higher in Tromsø 7 study, in particular among 
participants with diabetes. Substantial differences in 
mean risk factor levels were observed between KYH and 
Tromsø 7. Systolic and diastolic blood pressure were 
higher in KYH than in Tromsø 7, and smoking prevalence 
was higher among men and mean BMI and WC were 
higher among women in KYH compared with Tromsø 7 
(online supplemental table 6).
The age- adjusted odds of having diabetes in KYH 
were twice that in Tromsø 7 among men and more than 
three times higher among women, as shown by the size 
of the total effect in table 4. Differences in distribution 
of BMI and WC did not appear to explain any of the 
differences in diabetes prevalence between study popu-
lations among men. The estimation of natural indirect 
effect of all mediators considered (BMI, WC, hsCRP, 
smoking) among men yielded an OR of 1.07 (0.99, 1.16), 
which indicates a small contribution of mediators to the 
differences in diabetes prevalence between studies (total 
effect). This is reflected by a small mediated percentage: 
9.9% (−0.6, 20.8). On the contrary, the natural indirect 
effect of two measures of adiposity (BMI, WC) among 
women was estimated from an OR of 1.81 (1.68, 1.94), 
which corresponds to 46.0% (39.6, 53.8) of the diabetes 
differences between KYH and Tromsø 7 being explained 
by these two mediators. With addition of two remaining 
mediators (hsCRP and smoking), the natural indirect 
effect slightly increased to OR=2.04 (1.85, 2.26), which 
corresponds to 55.5% (46.5, 66.0) of the difference in 
prevalence between studies in women explained by all 
considered mediators (table 4). It was notable that the 
residual (natural direct effect) effects not mediated by 
BMI and WC were similar in men and women.
Sensitivity analysis
The results of the mediation analysis were similar if 
conducted separately for diagnosed and undiagnosed 
diabetes (online supplemental tables 4 and 5); however, 
the contribution of BMI and WC to the mediation was 
smaller for undiagnosed than diagnosed diabetes.
Sensitivity analysis using a diabetes case definition 
based solely on HbA1c values did not substantially 
change the findings of the mediation analysis or of the 
comparison of the CVD risk factor profile (data available 
from authors).
DISCUSSION
In this study we compared the prevalence of diabetes in 
two population- based studies conducted in Russia and 
Norway using the same case definitions. We found much 
higher prevalence of diabetes in KYH (11.6% in men 
and 13.2% in women) compared with Tromsø 7 (6.2% 
in men and 4.3% in women). The prevalence of diabetes 
was higher in women than in men in the Russian sample, 
which is the opposite of what is observed in Norway and 
other countries.4 5 We also found that there is a higher 
Table 2 Proportion of undiagnosed diabetes* among participants with measured HbA1c by sex and 15- year age groups in 
Tromsø 7 and Know Your Heart
Know your Heart Tromsø 7
Diabetes*† (n)
Undiagnosed diabetes*‡
% of diabetes cases (n) Diabetes (n)
Undiagnosed diabetes
% of diabetes cases (n)
Men
  Total sample 207 36.9 (76) 507 18.5 (94)
  40–54 years old 55 38.3 (23) 191 19.9 (38)
  55–69 years old 152 37.2 (58) 316 17.7 (56)
Women
  Total sample 342 26.8 (91) 389 12.3 (48)
  40–54 years old 55 45.6 (26) 144 8.3 (12)
  55–69 years old 287 23.7 (68) 245 14.7 (36)
*Number of diabetes and undiagnosed diabetes cases presented only for participants with complete data on HbA1c.
†Diabetes among participants with measured HbA1c was defined as HbA1c ≥6.5% (48 mmol/mol) and/or self- reported diabetes and/or use 
of medication with ATC code A10 (antidiabetics) according to the Anatomical Therapeutic Chemical (ATC) classification.
‡Undiagnosed diabetes among participants with measured HbA1c was defined as HbA1c ≥6.5% (48 mmol/mol), no self- reported diabetes 
and no diabetes medication use.
HbA1c, glycated hemoglobin.
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proportion of undiagnosed diabetes in Russia than in 
Norway, with proportions of previously undiagnosed 
diabetes of 36.9% among men and 26.8% among women 
in KYH.
We attempted to explain the differences in prevalence 
of diabetes between the two countries using mediation 
analysis and found that adiposity measured by BMI 
and WC could explain up to 46% of the difference in 
diabetes prevalence between studies in women, but did 
not explain the differences between studies observed in 
men. Taking further account of smoking and hsCRP as 
mediation factors in addition to adiposity could explain 
55.5% of the differences in diabetes prevalence between 
studies in women.
Our estimates of diabetes prevalence in Russia are in 
line with previous studies, although not all of them are 
published in the peer review literature or contain suffi-
cient detail on age- specific diabetes prevalence.7 10 11 23 
Two recent multiregion studies in Russia reported age- 
specific prevalence of diabetes and found that women 
at older ages have higher prevalence of diabetes than 
men.8 9 The NATION study (2013–2015) estimated type 
2 diabetes prevalence based on both HbA1c and self- 
report: 7.0% of women vs 7.9% of men aged 45–59 years 
old and 14.1% of women vs 9.9% of men aged 60–79 
years had diabetes.8 The ESSE- RF study (10 regions of 
the Russian Federation, 2012–2014) estimated the prev-
alence of diabetes mellitus based on self- report and 
fasting glucose: 9.4% of men and 7.4% of women aged 
45–54 years old and 13.6% of men and 16.5% of women 
aged 55–64 years old had diabetes mellitus.9 Similarly to 
our study, other studies conducted in Russia report that 
a high proportion of diabetes is undiagnosed: 54% in 
NATION study,8 43% in HAPIEE,10 and 27% in UEMS.11 
Differences between these estimates and estimates from 
our study can be explained by the different age structures 
of the studied populations, different access to healthcare 
services in Russian regions, and different methods for 
diabetes prevalence estimates.
According to the WHO STEPwise approach to surveil-
lance (STEPS) (2019), raised fasting blood glucose 
(≥7.0 mmol/L) or under medication for raised blood 
glucose was found in 7.1% of the Ukrainian popula-
tion: 6.7% of men and 7.4% of women (18–69 years 
old). Nearly half of them had not previously been diag-
nosed with diabetes.24 The percentage of population 
with diabetes is lower in Belarus (3.2 of men and 3.9 of 
women) and higher in the Republic of Moldova (11.5 
of men and 13.0 of women); however, in all three coun-
tries the prevalence of diabetes in women is higher than 
in men.25 The higher prevalence of diabetes in women 
than men observed in KYH is the opposite pattern to that 
observed in Norway and most other countries where the 
majority of the population are of European ancestry. The 
higher diabetes prevalence in men is usually explained by 
diverse biological, cultural, lifestyle, and environmental 
factors.26–29 Explanations for the pattern observed in 
Russia require further research. Certain cultural factors 
in Russia may be considered distal, that is, influencing 
behavior, and modify the biologically lower predisposi-
tion of women to develop diabetes.
Table 4 OR* showing natural direct and indirect effects† of study (KYH vs Tromsø 7) on diabetes‡ prevalence assessed from 
mediation analyses and mediated percentage for different sets of risk factors (BMI, waist circumference, smoking, hsCRP), by 
sex
Model 1
BMI and waist circumference included 
as mediators
Model 2
BMI, waist circumference, smoking, and 
hsCRP included as mediators
Men
  Natural direct effect 2.02 (1.70, 2.40) 1.87 (1.57, 2.24)
  Natural indirect effect 0.99 (0.95, 1.04) 1.07 (0.99, 1.16)
  Total effect 2.01 (1.68, 2.40) 2.01 (1.69, 2.38)
  Percentage mediated −1.1% (−8.9, 5.5) 9.9% (−0.6, 20.8)
Women
  Natural direct effect 1.99 (1.70, 2.35) 1.77 (1.49, 2.11)
  Natural indirect effect 1.81 (1.68, 1.94) 2.04 (1.85, 2.26)
  Total effect 3.66 (3.13, 4.26) 3.62 (3.10, 4.21)
  Percentage mediated 46.0% (39.6, 53.8) 55.5% (46.5, 66.0)
*Adjusted for age.
†Total effect of exposure is decomposed into natural direct and indirect effects. Natural indirect effect means effect of exposure that is 
mediated by a specific set of risk factors. Natural direct effect is the remaining effect of an exposure after quantifying the natural indirect 
effect. In our analysis, the study (KYH vs Tromsø 7) was considered the exposure, while diabetes risk factors were considered possible 
mediators.
‡Diabetes defined as HbA1c ≥6.5% (48 mmol/mol) and/or self- reported diabetes and/or use of medication with ATC code A10 (antidiabetics) 
according to the Anatomical Therapeutic Chemical (ATC) classification.
BMI, body mass index; HbA1c, glycated hemoglobin; hsCRP, high sensitivity C reactive protein; KYH, Know Your Heart.
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Estimates of the prevalence of diabetes in Norway 
are available from national registries with prospectively 
collected data on prescriptions of antidiabetic drugs and 
diabetes diagnoses from hospitals and primary care visits 
for all residents in Norway aged 30–89 years. Crude preva-
lence of type 2 diabetes increased from 4.9% to 6.1% from 
2009 to 2014, and diabetes prevalence was higher in men 
than in women (6.8% vs 5.3% in 2014).30 However, these 
estimates do not include undiagnosed diabetes cases that 
would be detected by screening. Intensive pharmacolog-
ical and lifestyle management of diabetes delays onset 
and slows the progression of diabetes complications.31 32 
Our study has shown that the proportion of undiagnosed 
diabetes is apparently smaller in the Norwegian study 
compared with the Russian study, but is still of significant 
public health concern given the potential health conse-
quences of unmanaged diabetes.33
Weight reduction and diet modification interventions 
in people with impaired glucose tolerance reduced the 
incidence of diabetes in randomized controlled trials.34 35 
Therefore, lifestyle interventions would be beneficial for 
both persons with clinically defined diabetes and persons 
with pre- diabetes.36 In our study prevalence of pre- 
diabetes was higher in KYH compared with Tromsø 
7, which means there is much potential for diabetes 
prevention. Incorporation of a broader definition of pre- 
diabetes (HbA1c ≥5.7% or fasting glucose ≥5.6 mmol/L) 
to the diagnosis guidelines in Russia may be justified to 
prevent more cases of diabetes with timely intervention 
if the change in cut- points is shown to be cost- effective.
Our data do not explain in full why prevalence of 
diabetes differs in Norway and Russia particularly among 
men. Our measures of adiposity (BMI and WC) explained 
a substantial proportion of difference among women 
(46%), but these factors did not make an important 
contribution to differences among men. Interestingly, 
after accounting for adiposity the remaining difference 
in diabetes prevalence between KYH and Tromsø 7 study 
was similar for men and women (double the odds of 
diabetes prevalence). It was previously shown even among 
people of European ancestry that differences exist in the 
relationship between body fat and BMI.37 Also, the associ-
ation of obesity and diabetes was shown to be stronger in 
low education groups, which suggests that socioeconomic 
circumstances may influence vulnerability to adiposity.38
It has been previously demonstrated that smoking 
is associated with diabetes, with a relative risk of 1.4 
(adjusted for the baseline BMI).22 39 hsCRP reflects the 
level of general inflammation and is positively associ-
ated with obesity and diabetes.21 As the prevalence of 
smoking and hsCRP levels are higher among Russian 
men compared with men in Norway, we expected them 
to contribute to some of the difference in diabetes preva-
lence. However, we did not observe an additional contri-
bution of these factors to explaining the differences 
in diabetes prevalence when adiposity measures were 
already included in the model. Among women, smoking 
and hsCRP made a small additional contribution to the 
difference in diabetes prevalence between studies after 
accounting for adiposity.
There are other potential explanations for the differ-
ences in diabetes prevalence between studies, such 
as diet,40 41 levels of physical activity,42 and sedentary 
behavior.43 Unfortunately, comparable data on these 
factors between our two studies are not available.
Type 2 diabetes is a multifactorial disease and involves 
genetic, behavioral and environmental factors, and their 
interaction.44 However, researchers still have a limited 
understanding of the genetic and epigenetic contribu-
tion to type 2 diabetes: only 10%–15% of heritability can 
be explained by known genetic variants.45 At the present 
time we do not have genomic data for both studies in 
order to investigate any differences between them.
Limitations
The major limitation of the mediation analysis in our 
study is the cross- sectional nature of the data. People 
who knew they had diabetes could have attempted to 
lose weight, increase physical activity, eat a healthier diet, 
and stop smoking. For example, lower LDL- cholesterol 
levels in participants with diabetes in Tromsø 7 study 
can in part be explained by higher use of lipid- lowering 
medications and changes in diet after diabetes diagnosis. 
Beyond this it is likely that our anthropometric measures 
of adiposity in the two populations failed to adequately 
capture differences in the extent of visceral abdominal 
adiposity, which is particularly strongly related to risk of 
diabetes.46 Validity of the mediation estimates is depen-
dent on the assumption of no uncontrolled confounding 
for the exposure–outcome, exposure–mediator, or 
mediator- outcome relations.20
Although we were not able to distinguish between type 
1 diabetes and type 2 diabetes in our study, our results 
will be principally driven by type 2 diabetes because it 
constitutes between 90% and 95% of all diabetes in these 
populations.4
Finally, care must be taken before generalizing the 
study findings to the populations of Russia and Norway 
as a whole. First, the studies were conducted in three 
cities whose characteristics will differ in some respects 
from the national populations. In addition there is the 
uncertainty about whether the participants we studied 
were representative of their own cities’ populations. The 
Tromsø 7 study had a good response rate (65%), as did 
the study in Arkhangelsk (68%), although in Novosibirsk 
the response rate was low (41%).14 The participants who 
did not attend the health check in KYH study were likely 
to have more adverse risk factor profile than those who 
did (online supplemental tables 2 and 3). However it is 
notable that our estimates of diabetes prevalence from 
KYH are consistent with those of other population- based 
studies in Russia. Similarly, prevalence estimates for 
diabetes in Tromsø 7 are similar to the study reporting 
diabetes prevalence in the whole of Norway. Potential 
explanatory (mediating) effects of specific biomedical 
markers are likely not to be affected.
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CONCLUSIONS
The major differences in diabetes prevalence between 
Russia and Norway have important implications for 
health services in Russia and could contribute to the 
differences in CVD mortality between the two countries. 
Adiposity indices, smoking and C reactive protein only 
partially explained the differences in diabetes prevalence 
between studies in women and did not explain differ-
ences between diabetes prevalence in men. A substantial 
proportion of unexplained differences remained and 
requires further investigation. People with undiagnosed 
diabetes are not prescribed recommended glucose- 
lowering, blood pressure- lowering and lipid- lowering 
drugs, as well as antismoking counseling, which can be 
expected to reduce the risk of CVD and other compli-
cations of diabetes. The proportion of undiagnosed 
diabetes in Russia is alarmingly high given potential 
health consequences for individuals and subsequent 
burden from avoidable complications of diabetes on the 
healthcare system.
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